Immunome Inc
IMNMLatest QuantConomy context for IMNM: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
20
Asset profile
Immunome Inc
QuantConomy has a structured record for IMNM. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- IMNM
- Name
- Immunome Inc
- Coverage
- 3 market/data records
- Sources
- alpaca fmp alphavantage sec nasdaq
Latest signal rows
Recent signals for IMNM
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| insider trade large sale | bearish | 53 | Jul 7, 11:04 PM | Barchas Isaac (Director) sold IMNM shares ($2.00M) - 83,094 shares - [moderate bearish signal] |
| insider trade executive trade | slightly bullish | 36 | Jul 7, 09:43 PM | Lechleider Robert (Chief Medical Officer) exercised options for IMNM shares ($0.48M) - 55,000 shares - [weak slightly bullish signal] |
| insider trade executive trade | slightly bullish | 36 | Jun 29, 08:56 PM | Lechleider Robert (Chief Medical Officer) exercised options for IMNM shares ($0.48M) - 55,000 shares - [weak slightly bullish signal] |
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| IMNM | NASDAQ | alpaca | Immunome, Inc. Common Stock |
| IMNM | NASDAQ | fmp | Immunome, Inc. |
| IMNM | NASDAQ | alphavantage | Immunome Inc |
Recent insider transactions
Buys, last 90d
1
Sells, last 90d
2
Rows
20
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Horn Kinney | CHIEF BUSINESS OFFICER | exercise | 1,092 | $12.92 | $14,109 | 4 on EDGAR |
| Jul 6, 2026 | Barchas Isaac | Director | sale | 83,094 | $24.11 | $2,003,396 | 4 on EDGAR |
| Jul 2, 2026 | Lechleider Robert | Chief Medical Officer | exercise | 55,000 | $8.73 | $480,150 | 4 on EDGAR |
| Jun 25, 2026 | Lechleider Robert | Chief Medical Officer | exercise | 55,000 | $8.73 | $480,150 | 4 on EDGAR |
| Jun 15, 2026 | Rosett Max | Chief Financial Officer | exercise | 60,000 | $1.05 | $63,000 | 4 on EDGAR |
| Jun 10, 2026 | BIENAIME JEAN JACQUES | Director | grant | 9,897 | — | — | 4 on EDGAR |
| Jun 10, 2026 | SCHAFER CAROL | Director | grant | 9,897 | — | — | 4 on EDGAR |
| Jun 10, 2026 | WAGENHEIM PHILIP | Director | grant | 9,897 | — | — | 4 on EDGAR |
| Jun 10, 2026 | SWAIN SANDRA M | Director | grant | 9,897 | — | — | 4 on EDGAR |
| Jun 10, 2026 | Boylan James P | Director | grant | 9,897 | — | — | 4 on EDGAR |
| Jun 10, 2026 | Barchas Isaac | Director | grant | 9,897 | — | — | 4 on EDGAR |
| Jun 5, 2026 | BIENAIME JEAN JACQUES | Director | sale | 500 | $19.44 | $9,720 | 4 on EDGAR |
| May 15, 2026 | BIENAIME JEAN JACQUES | Director | purchase | 5,000 | $20.70 | $103,500 | 4 on EDGAR |
| Apr 2, 2026 | Higgins Jack | Chief Scientific Officer | sale | 9,438 | $21.64 | $204,238 | 4 on EDGAR |
| Apr 2, 2026 | Rosett Max | Chief Financial Officer | exercise | 31,848 | $1.05 | $33,440 | 4 on EDGAR |
| Mar 30, 2026 | Higgins Jack | Chief Scientific Officer | gift | 6,291 | $0.00 | $0 | 4 on EDGAR |
| Mar 27, 2026 | SIEGALL CLAY B | President and CEO | purchase | 25,450 | $19.67 | $500,602 | 4 on EDGAR |
| Mar 20, 2026 | WAGENHEIM PHILIP | Director | sale | 36,800 | $20.47 | $753,296 | 4 on EDGAR |
| Mar 10, 2026 | BIENAIME JEAN JACQUES | Director | purchase | 1,000 | $22.12 | $22,120 | 4 on EDGAR |
| Dec 30, 2025 | SIEGALL CLAY B | President and CEO | purchase | 4,729 | $21.15 | $100,018 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Get the data
Query IMNM context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access